Market Cap
€74.2b
Last Updated
2020/02/19 21:31 UTC
Data Sources
Company Financials +
Executive Summary
Bayer Aktiengesellschaft operates as a life science company worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Established dividend payer and fair value.
Similar Companies
Share Price & News
How has Bayer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BAYN has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.8%
BAYN
-0.3%
DE Pharmaceuticals
0.2%
DE Market
1 Year Return
10.4%
BAYN
17.6%
DE Pharmaceuticals
14.4%
DE Market
Return vs Industry: BAYN underperformed the German Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: BAYN underperformed the German Market which returned 14.1% over the past year.
Shareholder returns
| BAYN | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.8% | -0.3% | 0.2% |
| 30 Day | -0.03% | 3.2% | 0.9% |
| 90 Day | 10.2% | 12.5% | 4.6% |
| 1 Year | 15.7%10.4% | 21.7%17.6% | 17.9%14.4% |
| 3 Year | -21.6%-30.0% | 41.4%25.2% | 15.7%5.6% |
| 5 Year | -30.7%-40.7% | 40.6%16.6% | 23.4%6.5% |
Price Volatility Vs. Market
How volatile is Bayer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
What To Know Before Buying Bayer Aktiengesellschaft (ETR:BAYN) For Its Dividend1 month ago | Simply Wall St
Should You Be Pleased About The CEO Pay At Bayer Aktiengesellschaft's (ETR:BAYN)2 months ago | Simply Wall St
Imagine Owning Bayer (ETR:BAYN) And Wondering If The 39% Share Price Slide Is JustifiedValuation
Is Bayer undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BAYN (€75.48) is trading below our estimate of fair value (€198.6)
Significantly Below Fair Value: BAYN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BAYN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: BAYN is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BAYN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BAYN is good value based on its PB Ratio (1.6x) compared to the DE Pharmaceuticals industry average (2.3x).
Next Steps
Future Growth
How is Bayer forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?
19.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BAYN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: BAYN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BAYN's is expected to become profitable in the next 3 years.
Revenue vs Market: BAYN's revenue (3% per year) is forecast to grow slower than the German market (5% per year).
High Growth Revenue: BAYN's revenue (3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BAYN's Return on Equity is forecast to be low in 3 years time (14.3%).
Next Steps
Past Performance
How has Bayer performed over the past 5 years?
-15.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BAYN is currently unprofitable.
Growing Profit Margin: BAYN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BAYN is unprofitable, and losses have increased over the past 5 years at a rate of -15.6% per year.
Accelerating Growth: Unable to compare BAYN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BAYN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-5%).
Return on Equity
High ROE: BAYN has a negative Return on Equity (-2.57%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Bayer's financial position?
Financial Position Analysis
Short Term Liabilities: BAYN's short term assets (€33.5B) exceed its short term liabilities (€26.1B).
Long Term Liabilities: BAYN's short term assets (€33.5B) do not cover its long term liabilities (€58.6B).
Debt to Equity History and Analysis
Debt Level: BAYN's debt to equity ratio (92%) is considered high.
Reducing Debt: BAYN's debt to equity ratio has increased from 69.8% to 92% over the past 5 years.
Balance Sheet
Inventory Level: BAYN has a low level of unsold assets or inventory.
Debt Coverage by Assets: BAYN's debt is not covered by short term assets (assets are 0.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BAYN has been profitable on average in the past, therefore cash runway is not a concern.
Forecast Cash Runway: BAYN has been profitable on average in the past, therefore cash runway is not a concern.
Next Steps
Dividend
What is Bayer's current dividend yield, its reliability and sustainability?
3.71%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: BAYN's dividend (3.71%) is higher than the bottom 25% of dividend payers in the German market (1.31%).
High Dividend: BAYN's dividend (3.71%) is in the top 25% of dividend payers in the German market (3.57%)
Stability and Growth of Payments
Stable Dividend: BAYN's dividends per share have been stable in the past 10 years.
Growing Dividend: BAYN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: BAYN is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: BAYN's dividends in 3 years are forecast to be well covered by earnings (39.6% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
Werner Baumann (57yo)
3.8yrs
Tenure
€6,361,000
Compensation
Mr. Werner Baumann has been Chairman of the Board of Management and Chief Executive Officer at Bayer AG since May 1, 2016 and has been its Member of Management Board since January 1, 2010. Mr. Baumann serv ...
CEO Compensation Analysis
Compensation vs Market: Werner's total compensation ($USD6.87M) is above average for companies of similar size in the German market ($USD4.36M).
Compensation vs Earnings: Werner's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board of Management & CEO | 3.8yrs | €6.36m | no data | |
| CFO & Member of Management Board | 1.7yrs | €2.58m | no data | |
| Member of Management Board | 4.1yrs | €3.02m | no data | |
| Head of Consumer Health Division & Member of Management Board | 1.9yrs | €4.09m | no data | |
| President of Pharmaceuticals Division & Member of the Board of Management | 1.3yrs | €2.10m | no data | |
| Head of Accounting and Head of Taxes | 3.8yrs | no data | no data | |
| Head of Investor Relations | 2.9yrs | no data | no data | |
| Head of Law | 0yrs | no data | no data | |
| Head of Communications | 3.8yrs | no data | no data | |
| Head of Mergers | 0yrs | no data | no data |
3.3yrs
Average Tenure
51yo
Average Age
Experienced Management: BAYN's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Supervisory Board | 17.8yrs | €204.00k | no data | |
| Chairman of Supervisory Board | 7.3yrs | €407.00k | no data | |
| Member of Supervisory Board | 3.8yrs | €274.00k | no data | |
| Chairman of Executive Board - Bayer Business Services | 0yrs | no data | no data | |
| Member of Supervisory Board | 13.3yrs | €136.00k | no data | |
| Vice Chairman of Supervisory Board | 4.6yrs | €273.00k | no data | |
| Chairman of Executive Board - Currenta | 0yrs | no data | no data | |
| Member of Supervisory Board | 7.8yrs | €205.00k | no data | |
| Member of Supervisory Board | 7.8yrs | €138.00k | no data | |
| Member of Supervisory Board | 1.8yrs | €165.00k | no data |
7.6yrs
Average Tenure
62.5yo
Average Age
Experienced Board: BAYN's board of directors are considered experienced (7.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.4%.
Top Shareholders
Company Information
Bayer Aktiengesellschaft's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bayer Aktiengesellschaft
- Ticker: BAYN
- Exchange: XTRA
- Founded: 1863
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €74.153b
- Shares outstanding: 982.42m
- Website: https://www.bayer.com
Number of Employees
Location
- Bayer Aktiengesellschaft
- Kaiser-Wilhelm-Allee 1
- Leverkusen
- North Rhine-Westphalia
- 51368
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BAYR.Y | OTCPK (Pink Sheets LLC) | SPONSORED ADR | US | USD | Dec 1972 | |
| BAYA | DB (Deutsche Boerse AG) | SPONSORED ADR | DE | EUR | Dec 1972 | |
| BAYA | XTRA (XETRA Trading Platform) | SPONSORED ADR | DE | EUR | Dec 1972 | |
| BAYZ.F | OTCPK (Pink Sheets LLC) | Yes | Registered Shares | US | USD | Jan 1975 |
| 0P6S | LSE (London Stock Exchange) | Yes | Registered Shares | GB | EUR | Jan 1975 |
| BAYN | DB (Deutsche Boerse AG) | Yes | Registered Shares | DE | EUR | Jan 1975 |
| BAYN | SWX (SIX Swiss Exchange) | Yes | Registered Shares | CH | CHF | Jan 1975 |
| BAY | BIT (Borsa Italiana) | Yes | Registered Shares | IT | EUR | Jan 1975 |
| BAYN | XTRA (XETRA Trading Platform) | Yes | Registered Shares | DE | EUR | Jan 1975 |
| BAYER | BUSE (Budapest Stock Exchange) | Yes | Registered Shares | HU | HUF | Jan 1975 |
| BAYN N | BMV (Bolsa Mexicana de Valores) | Yes | Registered Shares | MX | MXN | Jan 1975 |
| BAYN | WBAG (Wiener Boerse AG) | Yes | Registered Shares | AT | EUR | Jan 1975 |
| BAY1 | DB (Deutsche Boerse AG) | NPV (NEW) | DE | EUR | Jan 2018 |
Biography
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, cosmetics, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, cold and cough, foot care, and sun protection categories. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The Animal Health segment develops and markets products and solutions for the prevention and treatment of disease in companion and farm animals to veterinarians. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/19 21:31 |
| End of Day Share Price | 2020/02/19 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.